Research shows that superbugs are killed by ACTICOAT™ silver-coated antimicrobial dressings

Research shows that superbugs are killed by ACTICOAT™ silver-coated 
antimicrobial dressings 
ST. PETERSBURG, Fla., April 9, 2013 /CNW/ - Smith & Nephew (LSE: SN, NYSE: 
SNN), the global medical technology business, today announced in-vitro study 
results suggesting ACTICOAT Silver-Coated Antimicrobial Dressings are 
bactericidal against some antibiotic resistant organisms carrying the NDM-1 
enzyme, often referred to as 'superbugs'. 
An in-vitro laboratory study showed ACTICOAT Dressings, containing patented 
Nanocrystalline Silver technology, can kill the antibiotic resistant enzyme, 
New Delhi metallo-beta-lactamase 1 (NDM-1 bacteria strain)(3) which is carried 
by four of the same CRE bacteria cited by the CDC1. In this study, ACTICOAT 
Dressings killed Escherichia coli and Klebsiella spp.,(3) which are 
responsible for most carbapenem resistance in the United States(1). 
The Centers for Disease Control (CDC) issued statements recently to warn the 
public about antibiotic resistant organisms like carbapenem-resistant 
Enterobacteriaceae (CRE), raising concerns about the rise in the prevalence of 
these organisms and their associated high mortality rates(1). While the 
prevalence of CRE varies by geographic region, CRE organisms can spread their 
resistant genes to common bacteria, potentially resulting in the spread of 
untreatable infections. 
Reducing the spread of CRE is challenging for hospitals, rehabilitation 
facilities and nursing homes because these antibiotic resistant bacteria 
develop resistance to even the most powerful antibiotics which are often 
reserved as a last resort. According to the CDC, almost all CRE infections 
happen to patients who are receiving serious medical care(2). 
Dr. Jose Vazquez, MD, FACP, FIDSA, Professor of Medicine, Division of 
Infectious Diseases, Wayne State University School of Medicine, Senior Staff, 
Henry Ford Hospital, Detroit, MI uses ACTICOAT Dressings in his practice. He 
says: "Any opening in the skin provides an entry point for antibiotic 
resistant organisms. I use ACTICOAT Dressings in my practice because they 
provide an antimicrobial barrier that helps protect wounds and incision sites 
from external contamination. I continue to see excellent clinical results 
because ACTICOAT Dressings are bactericidal against five strains of bacteria 
that carry the NDM-1 enzyme and 360+ pathogens including 188 strains of MRSA." 
The Nanocrystalline Silver in ACTICOAT Dressings is different from the silvers 
used in other dressings because of its potency, fast kill action of 30 
minutes, and broad spectrum activity. ACTICOAT provides bactericidal activity 
for up to seven days, so it helps protect patients with wounds or incisions 
from environmental contamination, even after they leave the hospital. ACTICOAT 
is contra-indicated in patients with known hypersensitivity to any of the 
components of the product. (If signs of a sensitivity reaction develop during 
use, treatment should be discontinued.) 
"We share the same concerns as the CDC about antibiotic resistant organisms 
and are pleased that ACTICOAT Dressings are bactericidal against five 
different strains of bacteria that carry NDM-1 carbapenemases," said Tom 
Dugan, President, North America, Advanced Wound Management division, Smith & 
Nephew. "Making this information widely available is part of our obligation to 
address public health issues and support clinicians and the patients they 
serve, helping them to reduce the human and economic costs of wounds." 
For more information about Smith & Nephew, please visit 
References  1) CDC 2012 CRE Toolkit. Guidance for Control of 
Carbapenem-resistant Enterobacteriaceae.  2) CDC Vital Signs™ Report, March 
2013 3) Hope et al. (2012) The In-Vitro antibacterial activity of 
nanocrystalline silver dressings against bacteria with NDM-1 carbapenemase. 
Presented at European Wound Management Association Conference. Vienna. 
About Smith & Nephew 
Smith & Nephew is a global medical technology business dedicated to helping 
improve people's lives. With leadership positions in Orthopaedic 
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & 
Nephew has almost 10,500 employees and a presence in more than 90 countries. 
Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member 
of the FTSE100 (LSE: SN, NYSE: SNN). 
For more information about Smith & Nephew, please visit: 
Forward-looking Statements  This document may contain forward-looking 
statements that may or may not prove accurate. For example, statements 
regarding expected revenue growth and trading margins, market trends and our 
product pipeline are forward-looking statements. Phrases such as "aim", 
"plan", "intend", "anticipate", "well-placed", "believe", "estimate", 
"expect", "target", "consider" and similar expressions are generally intended 
to identify forward-looking statements. Forward-looking statements involve 
known and unknown risks, uncertainties and other important factors that could 
cause actual results to differ materially from what is expressed or implied by 
the statements. For Smith & Nephew, these factors include: economic and 
financial conditions in the markets we serve, especially those affecting 
health care providers, payors and customers; price levels for established and 
innovative medical devices; developments in medical technology; regulatory 
approvals, reimbursement decisions or other government actions; product 
defects or recalls; litigation relating to patent or other claims; legal 
compliance risks and related investigative, remedial or enforcement actions; 
strategic actions, including acquisitions and dispositions, our success in 
integrating acquired businesses, and disruption that may result from changes 
we make in our business plans or organisation to adapt to market developments; 
and numerous other matters that affect us or our markets, including those of a 
political, economic, business or competitive nature. Please refer to the 
documents that Smith & Nephew has filed with the U.S. Securities and Exchange 
Commission under the U.S. Securities Exchange Act of 1934, as amended, 
including Smith & Nephew's most recent annual report on Form 20-F, for a 
discussion of certain of these factors. 
Any forward-looking statement is based on information available to Smith & 
Nephew as of the date of the statement. All written or oral forward-looking 
statements attributable to Smith & Nephew are qualified by this caution. Smith 
& Nephew does not undertake any obligation to update or revise any 
forward-looking statement to reflect any change in circumstances or in Smith & 
Nephew's expectations. 
Investors/Analysts: Phil Cowdy, Smith & Nephew, +44 (0)20 7401 7646, or Media: 
Amy Phillips, EVC Group, +1 412 327 9499 
SOURCE: Smith & Nephew 
To view this news release in HTML formatting, please use the following URL: 
CO: Smith & Nephew
ST: Florida
-0- Apr/09/2013 11:01 GMT
Press spacebar to pause and continue. Press esc to stop.